wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35115922-0AE4518E-C315-4483-91C3-A2C752A20D8E
Q35115922-0AE4518E-C315-4483-91C3-A2C752A20D8E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35115922-0AE4518E-C315-4483-91C3-A2C752A20D8E
Aminolevulinic acid-photodynamic therapy combined with topically applied vascular disrupting agent vadimezan leads to enhanced antitumor responses
P2860
Q35115922-0AE4518E-C315-4483-91C3-A2C752A20D8E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35115922-0AE4518E-C315-4483-91C3-A2C752A20D8E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c7de35263826f14c142701690ccd806f368674c3
P2860
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.